Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

ENDRA Life Sciences (NDRA) EBITDA Margin (2016 - 2018)

ENDRA Life Sciences has reported EBITDA Margin over the past 3 years, most recently at 45960.77% for Q1 2018.

  • Quarterly EBITDA Margin changed N/A to 45960.77% in Q1 2018 from the year-ago period, while the trailing twelve-month figure was 146080.47% through Dec 2018, down 14476512.0% year-over-year, with the annual reading at 146080.47% for FY2018, 14476483.0% down from the prior year.
  • EBITDA Margin was 45960.77% for Q1 2018 at ENDRA Life Sciences, down from 33526.58% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 61.85% in Q4 2016 and troughed at 45960.77% in Q1 2018.
  • The 3-year median for EBITDA Margin is 1829.36% (2017), against an average of 16339.19%.
  • The largest YoY upside for EBITDA Margin was -3346474bps in 2017 against a maximum downside of -3346474bps in 2017.
  • A 3-year view of EBITDA Margin shows it stood at 61.85% in 2016, then crashed by -54107bps to 33526.58% in 2017, then plummeted by -37bps to 45960.77% in 2018.
  • Per Business Quant, the three most recent readings for NDRA's EBITDA Margin are 45960.77% (Q1 2018), 33526.58% (Q4 2017), and 317.4% (Q3 2017).